---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Indication questions"
description: "Indication questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Kisqali approved for in metastatic breast cancer? Can Kisqali be used in premenopausal and postmenopausal women? Can Kisqali be used after progression on endocrine therapy? Can Kisqali be used in patients with visceral metastases? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Indication questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Indication questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications: Indication](https://www.evicenter.com/medical-information/kisqali/indication).

## Indication

<a id="kisqali-indication"></a>

### What is Kisqali approved for in metastatic breast cancer?

> “KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in 
> combination with: 
> • 
> an aromatase inhibitor as initial endocrine-based therapy; or  
> • 
> fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.”

Source: [KISQALI: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=3)

Note: The Prescribing Information also lists an early breast cancer indication (adjuvant treatment with an aromatase inhibitor), which this page does not cover.

<a id="kisqali-menopausal-status"></a>

### Can Kisqali be used in premenopausal and postmenopausal women?

> “KISQALI<sup>®</sup> (ribociclib) is approved for premenopausal and postmenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), in combination with<sup>1</sup>: 
>
> an aromatase inhibitor (AI) as initial endocrine-based therapy; or 
>
> fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy (ET)”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-14](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=%28ribociclib%29%20is%20approved%20for%20premenopausal,progression%20on%20endocrine%20therapy%20%28ET%29)

This passage is in a collapsed section of the page; select: Which patients with metastatic breast cancer are appropriate for KISQALI?

> “Pre/perimenopausal women, or men, treated with the combination KISQALI plus an aromatase inhibitor or fulvestrant, 
> should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice 
> standards.”

Source: [KISQALI: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=3)

<a id="kisqali-after-progression"></a>

### Can Kisqali be used after progression on endocrine therapy?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

> “Yes, KISQALI<sup>®</sup> (ribociclib) can be used in combination with fulvestrant after disease progression on endocrine therapy (ET) in appropriate patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). This use is supported by clinical trial data, including from MONALEESA-3, which studied KISQALI + fulvestrant for first- and second-line (1L and 2L) postmenopausal patients with HR+/HER2- mBC who received no or only 1 line of prior ET for advanced disease.<sup>1</sup>”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=Yes%2C,of%20prior%20ET%20for%20advanced)

On the page, select: Can KISQALI be used after disease progression?

<a id="kisqali-visceral-disease"></a>

### Can Kisqali be used in patients with visceral metastases?

Applies to: Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

> “Yes, KISQALI<sup>®</sup> (ribociclib) can be used in appropriate patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), including patients with visceral disease. KISQALI was assessed in first-line (1L) patients with visceral metastases in an exploratory, pooled subgroup analysis of the 3 phase III MONALEESA trials. The results of this trial are exploratory and hypothesis-generating; as such, there was no statistical procedure controlling for type 1 error. Additionally, KISQALI was evaluated against combination chemotherapy in the phase II RIGHT Choice trial for patients with aggressive disease. Due to the nature of the study, results should be interpreted with caution. These results from a subgroup analysis of patients with aggressive disease who did not have visceral crisis are exploratory and hypothesis-generating; as such, there was no statistical procedure controlling for type 1 error. In the 3 phase III MONALEESA clinical trials, ≥50% of patients studied had visceral metastases.<sup>1,2</sup>”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=with%20visceral%20disease%3F-,Yes%2C,of%20patients%20studied%20had%20visceral)

On the page, select: Can KISQALI be used in patients with visceral disease?

> “Study design: This MONALEESA pooled analysis included 1889 patients from across the MONALEESA trials, of which 59.5% (n=1124) had visceral metastases; of the 1229 patients receiving 1L therapy, 57.7% (n=709) had visceral metastases. These results are exploratory and hypothesis-generating; as such, there was no statistical procedure controlling for type 1 error.<sup>1</sup>”

Source: [KISQALI: Aggressive & Visceral Disease | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/aggressive-visceral-disease#:~:text=Study%20design%3A%20This%20MONALEESA%20pooled,procedure%20controlling%20for%20type%201)

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
